This Special Issue of the journal Sensors will focus on “Network security and IoT Security”, with a broad focus on the following (but not exhaustive) list of topics: - IoT security threats and mitigation - Access management - Improved authentication - Wireless security - Firewalls and honeypots - Endpoint security - Digital piracy - Biometrics in security - Malware detection - Information security - Cloud security - Ransomware - Risk management - Digital forensics - Challenges in remote访问 - 数据存储安全性 - 数据丢失预防系统 - 社交媒体安全 - 密码学 - 区块链 - 移动应用程序安全
Introduction 7 FortiClient, FortiClient EMS, and FortiGate 7 Fortinet product support for FortiClient 7 FortiClient EMS 8 FortiManager 8 FortiGate 8 FortiAnalyzer 9 FortiSandbox 9 FortiClient standalone and licensed version feature comparison 9 Endpoint communication security 11 Recommended upgrade path 12 Getting started 17 Getting started with FortiClient 17 EMS and endpoint profiles 18 Telemetry connection options 18 EMS and automatic upgrade of FortiClient 21 Provisioning preparation 22 Installation requirements 22 Licensing 23 Required services and ports 23 Firmware images and tools 27 Microsoft Windows 27 macOS 28 Linux 28 Obtaining FortiClient installation files 29 Provisioning 30 Manually installing FortiClient on computers 30 Microsoft Windows 30 Microsoft Server 31 macOS 31 Linux 37 Installing FortiClient on infected systems 38 Installing FortiClient as part of cloned disk images 39使用CLI 39安装forticlient 39 forticlient部署40 ForticLient EMS 40使用Microsoft Ad Servers部署forticlient 40卸载ForticLient 41升级ForticLient 42验证FortiClient 42 EMS和ForticLient 44 Ports和Forticlient 44 Connectitive ems和Forticlient 44 Connectitive ems and Service and ems and Service and ems和FortiC 44
Malaysia的5G网络提供商数字Nasional Berhad(DNB),通过Menlo Security的安全企业浏览器解决方案为数百名分布式用户增强端点安全性。Menlo Secure Cloud浏览器与其现有安全堆栈无缝集成,从而在端点安全中缩小了空白。
主要终点 实验室确诊的拉沙临床疾病 次要终点 • 感染(可能转为共同主要终点) • 对先前免疫措施的分层分析 • 对不同谱系和/或进化枝的分层分析(筛选分析) • 死亡 • 风险的免疫相关性和保护替代物,即疫苗效力的替代物
Arista NDR平台通过集成到行业领先的SIEM,商业智能,票务和分析,端点检测以及安全编排工具来集成并扩大现有解决方案。此外,该平台还支持用于自定义工作流和集成的完整API。例如,SIEM集成允许分析师从包含IP或电子邮件地址的警报中旋转到具有关联的用户以及角色,操作系统和应用程序详细信息的设备配置文件,法医威胁时间表以及类似设备的列表以进行广告系列分析。同样,端点积分允许一键式隔离设备或端点法医数据的检索。
对提供空间供暖、制冷、生活热水和电力的太阳能冷热电联产 (S-CCHP) 系统进行了详细的“从摇篮到坟墓”的生命周期评估 (LCA),遵循两种不同的方法(ReCiPe 2016 Endpoint (H/A) v1.03 和碳足迹 IPCC 2013 100 年)。创新的 S-CCHP 系统目前正在位于西班牙萨拉戈萨的一座工业建筑中运行,开发的用于估算年能量产出的瞬态模型已经过验证。该系统由混合光伏热 (PV-T) 收集器组成,通过两个并联的储热罐与空气-水可逆热泵 (rev-HP) 集成。另一个贡献是,还对传统的 PV 系统和基于电网的系统进行了详细的 LCA 分析,即由电网供应的建筑用电量(基线配置)。结果表明,根据 ReCiPe 2016 Endpoint (H/A) 和 IPCC GWP 100a 方法,拟建的 S-CCHP 系统对环境的影响仅为电网系统的一半(分别为 4.48 kPts vs 8.87 kPts,82.4 吨二氧化碳当量 vs 166.9 吨二氧化碳当量)。光伏系统对环境的影响比电网系统小 30%。另一项新颖和贡献是进行敏感性分析,以评估系统寿命、太阳辐照度和发电结构(也称为电力结构)对 LCA 结果的影响。结果表明,在所有考虑的太阳辐照度水平和电力结构情景中,即使在低辐照度水平的气候条件或电力供应高度脱碳的国家,拟建的 S-CCHP 系统似乎是一种减少建筑物对环境影响的新兴替代方案。
1) 定义为端点非线性、滞后或重复性误差的 ±2 标准偏差限值。2) 定义为工作标准不准确度的 ±2 标准偏差限值,包括可追溯到国际标准。3) 定义为室温下端点非线性、滞后误差、重复性误差和校准不确定度的平方和根 (RSS)。4) 定义为工作温度范围内温度依赖性的 ±2 标准偏差限值。
Casgevy (exagamglogene autotemcel) is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). Casgevy was evaluated in an ongoing single-arm, multicenter, phase 1/2/3 trial with patients who had a history of at least 2 protocol-defined severe VOC events during each of the 2 years prior to screening. Of the 63 patients enrolled in the trial, 44 patients went on to receive Casgevy to form the full analysis set (FAS). Of the 44 patients from the FAS, 31 had adequate follow-up to allow evaluation of the primary efficacy endpoint and formed the primary efficacy set (PES). The primary efficacy outcome was the proportion of VF12 responders, defined as patients who did not experience any protocol-defined severe VOCs for at least 12 consecutive months within the first 24 months after treatment with Casgevy. The VF12 response rate was 29/31 (93.5%, 98% one-sided CI: 77.9%, 100.0%). The proportion of patients who did not require hospitalization due to severe VOCs for at least 12 consecutive months within the 24-month evaluation period (HF12) was also assessed. One patient was not evaluable for HF12 response; the remaining 30 patients achieved the endpoint of HF12 (100% [98% one-sided CI: 87.8%, 100.0%]). The most common grade 3 or 4 adverse reactions with an incidence ≥25% were mucositis, febrile neutropenia, and decreased appetite. The most common grade 3 or 4 laboratory abnormalities (≥ 50%) were neutropenia, thrombocytopenia, leukopenia, anemia, and lymphopenia.
* 定义为端点非线性、滞后或重复性误差的 ±2 标准偏差限值。** 定义为工作标准不准确性的 ±2 标准偏差限值,包括 NIST 的可追溯性。*** 定义为室温下端点非线性、滞后误差、重复性误差和校准不确定度的平方和根 (RSS)。**** 定义为工作温度范围内温度依赖性的 ±2 标准偏差限值。
1) 定义为端点非线性、滞后或重复性误差的 ±2 标准偏差限值。2) 定义为工作标准不准确性的 ±2 标准偏差限值,包括 NIST 的可追溯性。3) 定义为室温下端点非线性、滞后误差、重复性误差和校准不确定度的平方和根 (RSS)。4) 定义为工作温度范围内温度依赖性的 ±2 标准偏差限值。